VERICIGUAT TAB
Clinical Criteria Summary
Exclusion Criteria
- Symptomatic hypotension
- Concomitant use of other soluble guanylate cyclase stimulators (e.g., riociguat)
- Concomitant use of a PDE-5 inhibitor
- Pregnancy (i.e., known pregnancy or positive pregnancy test)
Inclusion Criteria
- Restricted to VA/VA Community Care cardiology provider or locally designated expert in the management of heart failure
- Left ventricular ejection fraction less than 45% with New York Heart Association class II-IV heart failure symptoms
- Recent evidence of worsening heart failure (e.g., hospitalization for heart failure within the past 6 months despite optimal medical therapy, or outpatient intravenous diuretic therapy within the previous 3 months)
- On guideline-directed therapy for heart failure with an ACEI, ARB, or ARNI; a beta-blocker; and a mineralocorticoid receptor antagonist (or unable to use these agents)
- Female patients of child-bearing potential: provided counseling on contraception and potential risks vs. benefits of treatment